CEO Marianne De Backer emphasized Vir's progress in advancing its infectious disease and oncology programs. Key milestones include initiating the ECLIPSE Phase III registrational program for hepatitis ...

First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...

ECLIPSE ABOUT WHAT SCIENTISTS ARE LOOKING FORWARD TO. WE ARE JUST DAYS AWAY FROM A RARE CELESTIAL EVENT A TOTAL ECLIPSE OF THE SUN ON APRIL 8TH. MORE THAN 31 MILLION PEOPLE WILL BE IN THE PATH OF ...

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is ...

ECLIPSE 3 is designed to compare the combination of tobevibart and elebsiran to bulevirtide in patients with chronic hepatitis delta SAN FRANCISCO, August 06, 2025--(BUSINESS WIRE)--Vir Biotechnology, ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and ...

The sun is about to pull another disappearing act across North America, turning day into night during a total solar eclipse.The peak spectacle on April 8 will last up to 4 minutes, 28 seconds in the ...

The sun is about to pull another disappearing act across North America, turning day into night during a total solar eclipse.The peak spectacle on April 8 will last up to 4 minutes, 28 seconds in the ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...